Barely Significant
← all excerpts

Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?

Cancer Med · 2019 · PMC6797580 · PMID 31475468

Europe PMCDOI
1
hedged sentence
0.1000
closest p · 2.0× alpha
0.1000
boldest claim

The sentences

did not reach statistical significanceP = 0.1so close (0.05 < p ≤ 0.1)
showed a trendP = 0.1so close (0.05 < p ≤ 0.1)
Provenzano et al 57 combined GEM with PEGPH20, a drug‐depleting HA, and observed significantly prolonged median survival (median overall survival of GEM‐ (55.5 days) and GEM + PEGPH20 (91.5 days)‐treated mice were significantly different ( P = 0.004); treatment with PEGPH20 alone showed a trend toward increased survival (median = 63 days) that did not reach statistical significance ( P = 0.1)).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.